Tirzepatide
Approved · EMAAlso known as Mounjaro, Zepbound.
Recent clinical, regulatory, research and industry developments relating to this drug.
The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
Ozempic and Mounjaro linked to a surprising hair loss risk
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
GLP-1 and the cardiovascular system.
Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.
Effects of patient age on the therapeutic effects of GIP/GLP-1 receptor agonists (tirzepatide).
Evidence confidence
How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.
— 10 supporting evidence families · 1 well-powered no-effect result
Confidence is moderated by well-powered no-effect evidence and limited publication incorporation, despite broad trial support.
High point estimate, but substantial uncertainty remains.
Confidence has a moderate point estimate but a wide uncertainty band — the evidence base is still thin.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as… Show full indicationShow less
Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1. Weight management Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obesity) or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Diabetes, obesity & metabolism7
- Cardiovascular diabetology2
- JAMA network open2
- Molecular metabolism2
- The Journal of clinical investigation2
- Cell metabolism1
- Coskun T4
- Nauck MA4
- Urva S4
- D'Alessio DA3
- Haupt A3
- Sloop KW3
- Alsina-Fernandez J2
- Barbieri M2
- College of Medicine2
- Duke University Medical Center2
- International Medical University2
- University of Campania "Luigi Vanvitelli"2
- University of Utah2
- "Attikon" University Hospital1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 16 of the same disease areas as Tirzepatide in the shared literature.
Studied across 11 of the same disease areas as Tirzepatide in the shared literature.
Studied across 14 of the same disease areas as Tirzepatide in the shared literature.
Studied across 8 of the same disease areas as Tirzepatide in the shared literature.
Studied across 8 of the same disease areas as Tirzepatide in the shared literature.
Studied across 7 of the same disease areas as Tirzepatide in the shared literature.
Studied across 6 of the same disease areas as Tirzepatide in the shared literature.
Studied across 6 of the same disease areas as Tirzepatide in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- Regulatory event sources are credited in the Regulatory Timeline above.